Résumé
The objective of the present study was to examine the relative contributions of different dimensions of catastrophic thinking (i.e. rumination, magnification, helplessness) to the pain experience and disability associated with neuropathic pain. Eighty patients with diabetic neuropathy, post-herpetic neuralgia, post-surgical or post-traumatic neuropathic pain who had volunteered for participation in a clinical trial formed the basis of the present analyses. Spontaneous pain was assessed with the sensory and affective subscales of the McGill Pain Questionnaire. Pinprick hyperalgesia and dynamic tactile allodynia were used as measures of evoked pain. Consistent with previous research, individuals who scored higher on a measure of catastrophic thinking (Pain Catastrophizing Scale; PCS) also rated their pain as more intense, and rated themselves to be more disabled due to their pain. Follow up analyses revealed that the PCS was significantly correlated with the affective subscale of the MPQ but not with the sensory subscale. The helplessness subscale of the PCS was the only dimension of catastrophizing to contribute significant unique variance to the prediction of pain. The PCS was not significantly correlated with measures of evoked pain. Catastrophizing predicted pain-related disability over and above the variance accounted for by pain severity. The findings are discussed in terms of mechanisms linking catastrophic thinking to pain experience. Treatment implications are addressed.
Langue d'origine | English |
---|---|
Pages (de-à) | 310-315 |
Nombre de pages | 6 |
Journal | Pain |
Volume | 113 |
Numéro de publication | 3 |
DOI | |
Statut de publication | Published - févr. 2005 |
Note bibliographique
Funding Information:The authors thank Dr Jana Sawynok for helpful comments and suggestions on a previous version of this paper. The authors also thank Paulette Naus for her assistance in data collection and Nathalie Gauthier and Isabelle Tremblay who completed data entry for this project. The work reported in this paper is drawn from a clinical trial funded by EpiCept Corporation. This work was partially supported by a grant from the Canadian Institutes for Health Research awarded to the first author.
ASJC Scopus Subject Areas
- Neurology
- Clinical Neurology
- Anesthesiology and Pain Medicine